EDUCATIONAL REFERENCE

Peptide Reference

Plain-English background with FDA safety and regulatory context. This is informational, not a recommendation to use these substances.

BPC-157

FDA has identified no or only limited safety-related information for proposed routes of administration and has said it lacks sufficient information to know whether BPC-157 would cause harm.

TB-500

FDA has stated that it did not identify human exposure data for TB-500 and lacks important information about potential safety issues.

CJC-1295

FDA has described limited clinical data and safety concerns for compounded CJC-1295, including immunogenicity concerns for injectable forms.

GHK-Cu

FDA has noted limited human data for injectable GHK-Cu and potential immunogenicity concerns.

MOTS-c

FDA has stated that it has not identified human exposure data for drug products containing MOTS-c and lacks important safety information.

Primary source: U.S. Food and Drug Administration materials on bulk drug substances and the July 23–24, 2026 Pharmacy Compounding Advisory Committee. PeptideQuick does not sell peptides or provide treatment, dosing, injection, or reconstitution instructions for unapproved substances.